Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Intraventricular B7-H3–Targeted CAR T-Cell Therapy Displays Safety in Recurrent Glioblastoma

November 25th 2025

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

FDA Approves Perioperative Durvalumab for Resectable Gastric/GEJ Adenocarcinoma

November 25th 2025

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

Cevostamab-Based Combos Could Represent Next Bispecific Antibody Approach in R/R Myeloma

November 25th 2025

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

European Commission Approves Liso-Cel for R/R Mantle Cell Lymphoma

November 25th 2025

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC

November 25th 2025

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

Dr Kline on Updated Efficacy Data With Tovorafenib in R/R Pediatric Low Grade Glioma

November 24th 2025

Cassie Kline, MD, MAS, discusses 3-year follow-up data with tovorafenib in patients with pediatric low-grade glioma from FIREFLY-1.

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

November 24th 2025

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.

Dr Grommes on the Addition of Ibrutinib to R-MPV Induction in Newly Diagnosed PCNSL

November 24th 2025

Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.

Dr Schaff on a Phase 1 Study of Copanlisib Plus Ibrutinib in Relapsed/Refractory PCNSL

November 24th 2025

Lauren Shaff, MD, contextualizes results from a phase 1 study evaluating copanlisib plus ibrutinib in relapsed/refractory primary and secondary CNS lymphoma.

FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer After Prior Enfortumab Vedotin

November 24th 2025

The FDA granted fast track designation to AVZO-103 for urothelial cancer previously treated with enfortumab vedotin.

Dr Nayak on Findings From the PROSPECT Trial of Tirabrutinib in Relapsed/Refractory PCNSL

November 24th 2025

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC

November 24th 2025

Sacituzumab tirumotecan plus pembrolizumab improved PFS as first-line treatment in PD-L1–positive advanced NSCLC.

Patient Factors Drive Chemotherapy Decision-Making in Metastatic Pancreatic Cancer

November 24th 2025

Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.

Sequential ICV/IV C7R-GD2 CAR T-Cell Therapy Is Better Tolerated in Pediatric CNS Tumors

November 24th 2025

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

Lutetium Lu 177 Dotatate Shows Promise in Advanced Intracranial Meningioma

November 23rd 2025

Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.

Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma

November 23rd 2025

Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.

Dr de la Fuente on Safety Data With Vorasidenib Plus Temozolomide in IDH-Mutant Glioma

November 23rd 2025

Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.

Dr Kurz on the Efficacy and Safety of Lutetium Lu 177 Dotatate in Advanced Intracranial Meningioma

November 22nd 2025

Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.

Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma

November 22nd 2025

Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.

CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer

November 22nd 2025

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.